ArticleThe Kaohsiung journal of medical sciences2026
ZFP36L1 Enhances Microglial Ferroptosis in Ischemic Stroke by Reducing FTO-Mediated N6-Methyladenosine Demethylation of ACSL1 mRNA.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Microglia play an important role in ischemic stroke (IS). However, the molecular regulatory mechanisms underlying microglial ferroptosis in IS remain incompletely understood. In this study, blood samples were collected from 20 IS patients and 15 healthy volunteers. Microglia BV-2 subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) and mice undergoing middle cerebral artery occlusion-reperfusion (MCAO/R) surgery were used to establish IS models. Our results revealed that in blood samples from IS patients and in OGD/R-treated BV-2 cells, ZFP36 ring finger protein like 1 (ZFP36L1) and Acyl-CoA synthetase long chain family member 1 (ACSL1) expression was increased, while the fat mass and obesity-associated (FTO) protein expression was decreased. ACSL1 silencing attenuated ferroptosis and inflammation in OGD/R-treated microglia, as evidenced by decreased levels of malondialdehyde, Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.